CAJ | 학술논문

目的探讨膀胱尿路上皮癌患者临床血清CA125检测与肿瘤病理之间的联系.方法对我科2003年8月至2015年3月就诊的251例膀胱尿路上皮癌患者(病例组)行膀胱镜病理及影像学检查明确病理类型,同时行血清CA125检测,观察不同类型病理的CA125检测结果,并进行统计学分析.同时选取100例正常成人行血清CA125检测作为对照组.结果 100例正常人CA125均阴性表达,251例膀胱尿路上皮癌患者中CA125阴性表达92例,占36.7%,阳性表达159例,占63.3%;CA125阳性表达在单发肿瘤中100例,多发肿瘤59例;两者比较差异无统计学意义(P>0.05);122例瘤体≤1.5 cm的患者中阳性表达78例,129例瘤体>1.5 cm的患者中阳性表达81例,两者比较差异无统计学意义(P>0.05);57例G1级肿瘤中阳性表达15例,占26.32%,139例G2级肿瘤中阳性表达95例,占68.35%,55例G3级肿瘤中阳性表达49例,占89.09%,G1级与G2级比较(P=0.041)、G1级与G3级比较(P=0.033)、G2级与G3级比较(P=0.015)差异均有统计学意义;14例Tis期阳性表达1例,占7.14%,115例T1期阳性表达64例,占55.65%,61例T2期阳性表达38例,占62.30%,34例T3期阳性表达31例,占91.18%,27例T4期阳性表达25例,占92.59%,Tis期与T1期比较差异无统计学意义(P=0.925),而T1期与T2期比较(P=0.031)、T2期与T3期比较(P=0.013)、T3期与T4期比较(P=0.008)差异均有统计学意义.结论膀胱尿路上皮癌患者中CA125的阳性表达与肿瘤数目及大小无关;与肿瘤的病理分级和临床分期相关;随着肿瘤级别和临床分期的改变,不同级别和分期的肿瘤阳性表达率逐渐升高,并与肿瘤的浸润有相关性.
목적 탐토방광뇨로상피암환자림상혈청CA125검측여종류병리지간적련계.방법 대아과2003년8월지2015년3월취진적251례방광뇨로상피암환자(병례조)행방광경병리급영상학검사명학병리류형,동시행혈청CA125검측,관찰불동류형병리적CA125검측결과,병진행통계학분석.동시선취100례정상성인행혈청CA125검측작위대조조.결과 100례정상인CA125균음성표체,251례방광뇨로상피암환자중CA125음성표체92례,점36.7%,양성표체159례,점63.3%;CA125양성표체재단발종류중100례,다발종류59례;량자비교차이무통계학의의(P>0.05);122례류체≤1.5 cm적환자중양성표체78례,129례류체>1.5 cm적환자중양성표체81례,량자비교차이무통계학의의(P>0.05);57례G1급종류중양성표체15례,점26.32%,139례G2급종류중양성표체95례,점68.35%,55례G3급종류중양성표체49례,점89.09%,G1급여G2급비교(P=0.041)、G1급여G3급비교(P=0.033)、G2급여G3급비교(P=0.015)차이균유통계학의의;14례Tis기양성표체1례,점7.14%,115례T1기양성표체64례,점55.65%,61례T2기양성표체38례,점62.30%,34례T3기양성표체31례,점91.18%,27례T4기양성표체25례,점92.59%,Tis기여T1기비교차이무통계학의의(P=0.925),이T1기여T2기비교(P=0.031)、T2기여T3기비교(P=0.013)、T3기여T4기비교(P=0.008)차이균유통계학의의.결론 방광뇨로상피암환자중CA125적양성표체여종류수목급대소무관;여종류적병리분급화림상분기상관;수착종류급별화림상분기적개변,불동급별화분기적종류양성표체솔축점승고,병여종류적침윤유상관성.
Objective To investigate the correlation between detection of serum CA125 in bladder urothelial carcinoma and the pathology of the tumor. Methods A total of 251 patients of bladder urothelial carcinoma in our de-partment from August 2003 to March 2015 (the study group) underwent pathological and imaging examination in cys-toscopy for pathological type, and the serum CA125 levels were also detected. The CA125 detection results of differ-ent pathological types were observed. At the same time, 100 healthy adult people were selected and underwent serum CA125 detection (the control group). Results In the control group, the expression of CA125 was negative in all the patients. In the study group, CA125 was negatively expressed in 92 cases (36.7%) and positively expressed in 159 cas-es (63.3%), including 100 cases of solitary tumor and 59 cases of multiple tumor, with no statistically significant differ-ence (P>0.05). CA125 was positively expressed in 78 of the 122 patients with tumors≤1.5 cm and in 81 of the 129 pa-tients with tumors>1.5 cm, showing no statistically significant difference (P>0.05). Positive expression of CA125 was found in 15 of the 57 patients of G1 grade tumor (accounting for 26.32%), 95 of the 139 patients of G2 grade tumor (68.35%), 49 of the 55 patients of G3 grade tumor (89.09%), with statistically significant difference between G1 grade and G2 grade (P=0.041), G1 grade and G3 grade (P=0.033), as well as G2 grade and G3 grade (P=0.015). CA125 was positively expressed in 1 of the 14 patients of Tis stage (7.14%), 64 of the 115 patients of T1 stage (55.65%), 38 of the 61 patients of T2 stage (62.30%), 31 of the 34 patients of T3 stage (91.18%), as well as 25 of the 27 patients of T4 stage(92.59%), with no statistically significant difference between Tis stage and T1 stage (P=0.925), but statistically signifi-cant difference between T1 stage and T2 stage (P=0.031), T2 stage and T3 stage (P=0.013), T3 stage and T4 stage (P=0.008). Conclusion Positive expression of CA125 in patients of bladder urothelial carcinoma show no correlation with the number and size of tumor, but it is associated with the pathological grading and clinical staging of tumor. With the increase of the pathological grade and clinical stage, the positive expression rate of CA125 rise gradually, which has correlation with tumor infiltration.